Results 1-69 of 69 (Search time: 0.025 seconds).
Issue Date | Title | Author(s) | Source | scopus | WOS | Fulltext/Archive link | |
---|---|---|---|---|---|---|---|
1 | 2023 | Sarcopenia and myosteatosis are associated with survival in patients receiving immunotherapy for advanced hepatocellular carcinoma | BANG-BIN CHEN ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH ; TSUNG-HAO LIU ; YING-CHUN SHEN ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | European radiology | 20 | 13 | |
2 | 2023 | Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial | Heo, Jeong; JA-DER LIANG ; Kim, Chang Won; Woo, Hyun Young; I-LUN SHIH ; TUNG-HUNG SU ; ZHONG-ZHE LIN ; Yoo, So Young; Chang, Stanley; Urata, Yasuo; PEI-JER CHEN | Molecular therapy : the journal of the American Society of Gene Therapy | 4 | 1 | |
3 | 2023 | Synergistic efficacy of telomerase-specific oncolytic adenoviral therapy and histone deacetylase inhibition in human hepatocellular carcinoma | ZHONG-ZHE LIN ; Hu, Mickey C-T; CHIUN HSU ; YAO-MING WU ; YEN-SHEN LU ; Ho, Ja-An Annie; Shiou-Hwei Yeh ; PEI-JER CHEN ; ANN-LII CHENG | Cancer letters | 1 | 1 | |
4 | 2022 | Association of annexin A10 expression with poor prognosis of intrahepatic cholangiocarcinoma | YU-YUN SHAO ; HUNG-YANG KUO ; YUNG-MING JENG ; YAO-MING WU ; HSIU-PO WANG ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | BMC cancer | 3 | 3 | |
5 | 2022 | The Long-Term and Mediating Effects of Mindfulness Integrated with Body-Mind-Spirit Group Therapy on Depressive Symptoms and Quality of Life Among Non-small Cell Lung Cancer Patients | FEI-HSIU HSIAO ; ZHONG-ZHE LIN ; Huang F.-Y.; Lai Y.-M.; Chen Y.-T.; JIN-YUAN SHIH ; CHAO-CHI HO ; CHONG-JEN YU ; Hsieh C.-C. | Mindfulness | 1 | 1 | |
6 | 2022 | Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade | Kelley R.K.; Miksad R.; Cicin I.; Chen Y.H.; Kl?mpen H.-J.; Kim S.; ZHONG-ZHE LIN ; Youkstetter J.; Hazra S.; Sen S.; ANN-LII CHENG ; El-Khoueiry A.B.; Meyer T.; Abou-Alfa G.K. | British Journal of Cancer | 17 | 14 | |
7 | 2021 | Revisiting Hepatic Artery Infusion Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma | Chen, Ching-Tso; TSUNG-HAO LIU ; YU-YUN SHAO ; KAO-LANG LIU ; PO-CHIN LIANG ; ZHONG-ZHE LIN | International journal of molecular sciences | 17 | 8 | |
8 | 2021 | Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials | BANG-BIN CHEN ; ZHONG-ZHE LIN ; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Cancers | 4 | 3 | |
9 | 2021 | Dynamic Contrast-Enhanced and Intravoxel Incoherent Motion MRI Biomarkers Are Correlated to Survival Outcome in Advanced Hepatocellular Carcinoma | BANG-BIN CHEN ; YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG ; CHIUN HSU ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Diagnostics (Basel, Switzerland) | 7 | 7 | |
10 | 2021 | The Short- and Long-term Causal Relationships Between Self-compassion, Trait Mindfulness, Caregiver Stress, and Depressive Symptoms in Family Caregivers of Patients with Lung Cancer | Hsieh, Chia-Chen; ZHONG-ZHE LIN ; CHAO-CHI HO ; CHONG-JEN YU ; Chen, Hsiu-Jung; Chen, Yu-Wen; FEI-HSIU HSIAO | Mindfulness | 4 | 3 | |
11 | 2021 | Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy | YING-CHUN SHEN ; Yeh C.-P.; YUNG-MING JENG ; CHIUN HSU ; CHIH-HUNG HSU ; ZHONG-ZHE LIN ; YU-YUN SHAO ; LI-CHUN LU ; TSUNG-HAO LIU ; CHIEN-HUNG CHEN ; ANN-LII CHENG | Cancers | 2 | 2 | |
12 | 2021 | Trait mindfulness and depressive symptoms in non-small cell lung cancer patients: the mediating roles of quality of life and meaning in life | Hsieh C.-C.; CHAO-CHI HO ; ZHONG-ZHE LIN ; CHONG-JEN YU ; Jow G.-M.; Huang F.-Y.; JIN-YUAN SHIH ; FEI-HSIU HSIAO | Psychology and Health | 2 | 4 | |
13 | 2021 | Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma | YU-YUN SHAO ; Sun, Nai-Yun; YUNG-MING JENG ; YAO-MING WU ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | Cells | 3 | 2 | |
14 | 2020 | A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy | ZHONG-ZHE LIN ; BANG-BIN CHEN ; Hung, Yi-Ping; HUANG, PO-HSIANG ; Ying-Chun Shen ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG ; Lee, Rheun-Chuan; Chao, Yee; CHIUN HSU | Oncologist | 12 | 10 | |
15 | 2020 | Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer | WEN-CHI YANG ; Feng-Ming Hsu ; YU-HSUAN CHEN ; JIN-YUAN SHIH ; CHONG-JEN YU ; ZHONG-ZHE LIN ; Lu S.-H.; CHIH-HSIN YANG ; ANN-LII CHENG ; SUNG-HSIN KUO | Clinical and Translational Radiation Oncology | 11 | 8 | |
16 | 2019 | Considerations of heterogeneity in clinical trials for hepatocellular carcinoma | TSUNG-HAO LIU ; YU-YUN SHAO ; LI-CHUN LU ; Ying-Chun Shen ; CHIUN HSU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; ANN-LII CHENG | Expert Review of Gastroenterology and Hepatology | 5 | 7 | |
17 | 2019 | Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations | YEN-TING LIN ; JIN-SHING CHEN ; WEI-YU LIAO ; CHAO-CHI HO ; CHIA-LIN HSU ; Yang C.-Y.; KUAN-YU CHEN ; JIH-HSIANG LEE ; ZHONG-ZHE LIN ; JIN-YUAN SHIH ; CHIH-HSIN YANG ; CHONG-JEN YU | International Journal of Cancer | 53 | 46 | |
18 | 2019 | Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; CHIUN HSU ; LI-CHUN LU ; YING-CHUN SHEN ; ZHONG-ZHE LIN ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver International | 58 | 58 | |
19 | 2019 | Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; CHIA-CHI LIN ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 27 | 24 | |
20 | 2019 | A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma | Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN ; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T. | Therapeutic Advances in Medical Oncology | 38 | 38 | |
21 | 2019 | First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma | Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN ; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. | Cancer Discovery | 154 | 136 | |
22 | 2019 | Development and validation of nomograms for predicting survival probability of patients with advanced adenocarcinoma in different EGFR mutation status | Chen H.-C.; Tan E.C.-H.; Liao C.-H.; ZHONG-ZHE LIN ; MING-CHIN YANG | PLoS ONE | 2 | 3 | |
23 | 2019 | Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma | ZHONG-ZHE LIN ; CHIUN HSU ; YUNG-MING JENG ; Hu F.-C.; Pan H.-W.; YAO-MING WU ; Hsu H.-C.; ANN-LII CHENG | Liver International | 18 | 18 | |
24 | 2017 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy | YU-YUN SHAO ; BANG-BIN CHEN ; DA-LIANG OU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; Wang, M. J.; ANN-LII CHENG ; CHIUN HSU | Alimentary Pharmacology and Therapeutics | 10 | 8 | |
25 | 2017 | Real-world data on prognostic factors for overall survival in EGFR mutation-positive advanced non-small cell lung cancer patients treated with first-line gefitinib | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; Chia-Chi Lin ; CHIH-HSIN YANG ; CHONG-JEN YU | Oncologist | 25 | 25 | |
26 | 2017 | Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) | Abou-Alfa G.K.; Yen C.-J.; CHIH-HUNG HSU ; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; YU-YUN SHAO ; ZHONG-ZHE LIN ; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG ; Carrasquilo J.A. | Cancer Chemotherapy and Pharmacology | 20 | 19 | |
27 | 2016 | Primary tumor site is a useful predictor of cetuximab efficacy in the third-line or salvage treatment of KRAS wild-type (exon 2 non-mutant) metastatic colorectal cancer: A nationwide cohort study | KUO-HSING CHEN ; YU-YUN SHAO ; Chen H.-M.; Lin Y.-L.; ZHONG-ZHE LIN ; Lai M.-S.; ANN-LII CHENG ; KUN-HUEI YEH | BMC Cancer | 41 | 39 | |
28 | 2015 | Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma | BIN-CHI LIAO ; YU-YUN SHAO ; Chen H.-M.; Shau W.-Y.; ZHONG-ZHE LIN ; Kuo R.N.; Lai C.-L.; KUO-HSING CHEN ; ANN-LII CHENG ; CHIH-HSIN YANG ; Lai M.-S. | Clinical Lung Cancer | 11 | 8 | |
29 | 2015 | The response, outcome and toxicity of aggressive palliative thoracic radiotherapy for metastatic non-small cell lung cancer patients with controlled extrathoracic diseases | YUN CHIANG ; CHIH-HSIN YANG ; Feng-Ming Hsu ; YU-HSUAN CHEN ; JIN-YUAN SHIH ; ZHONG-ZHE LIN ; KENG-HSUEH LAN ; ANN-LII CHENG ; SUNG-HSIN KUO | PLoS ONE | 9 | 9 | |
30 | 2015 | The prognostic impact of type 2 diabetes mellitus on early cervical cancer in Asia | HUNG-YANG KUO ; ZHONG-ZHE LIN ; Kuo R.; Shau W.-Y.; Lai C.-L.; Yang Y.-Y.; YU-YUN SHAO ; CHIUN HSU ; WEN-FANG CHENG ; ANN-LII CHENG ; CHIH-HSIN YANG ; Lai M.-S. | Oncologist | 10 | 10 | |
31 | 2015 | Statin Use Is Associated With Improved Prognosis of Colorectal Cancer in Taiwan | YU-YUN SHAO ; CHIH-HUNG HSU ; KUN-HUEI YEH ; Chen H.-M.; Yeh Y.-C.; Lai C.-L.; ZHONG-ZHE LIN ; ANN-LII CHENG ; Lai M.-S. | Clinical Colorectal Cancer | 35 | 32 | |
32 | 2015 | Young patients with colorectal cancer have increased risk of second primary cancers | YI-HSIN LIANG ; YU-YUN SHAO ; Chen H.-M.; Lai C.-L.; ZHONG-ZHE LIN ; Kuo R.N.; ANN-LII CHENG ; KUN-HUEI YEH ; Lai M.-S. | Japanese Journal of Clinical Oncology | 12 | 11 | |
33 | 2014 | Radiosensitization by combining an aurora kinase inhibitor with radiotherapy in hepatocellular carcinoma through cell cycle interruption | ZHONG-ZHE LIN ; Chou, Chia-Hung; ANN-LII CHENG ; Liu, Wei-Lin; CHIA-HSIEN CHENG | Int. J. Cancer | 17 | 15 | |
34 | 2014 | Phase ii multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer | Ying-Chun Shen ; Li C.-P.; Yen C.-J.; CHIUN HSU ; Lin Y.-L.; ZHONG-ZHE LIN ; Chen L.-T.; Su W.-C.; Chao Y.; KUN-HUEI YEH ; ANN-LII CHENG | Oncology (Switzerland) | 15 | 12 | |
35 | 2014 | Potential synergistic anti-tumor activity between lenalidomide and sorafenib in hepatocellular carcinoma | DA-LIANG OU ; Chang C.-J.; YUNG-MING JENG ; Lin Y.-J.; ZHONG-ZHE LIN ; Gandhi A.K.; Liao S.-C.; Huang Z.-M.; CHIUN HSU ; ANN-LII CHENG | Journal of Gastroenterology and Hepatology (Australia) | 11 | 13 | |
36 | 2014 | Type 2 diabetes mellitus is associated with increased mortality in chinese patients receiving curative surgery for colon cancer | KUO-HSING CHEN ; YU-YUN SHAO ; ZHONG-ZHE LIN ; Yeh Y.-C.; Wen-Yi S.; Kuo R.N.; Chen H.-M.; Lai C.-L.; KUN-HUEI YEH ; ANN-LII CHENG ; Lai M.-S. | Oncologist | 24 | 19 | |
37 | 2013 | Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size | ZHONG-ZHE LIN ; Shau W.-Y.; CHIUN HSU ; YU-YUN SHAO ; Yeh Y.-C.; Kuo R.N.-C.; CHIH-HUNG HSU ; CHIH-HSIN YANG ; ANN-LII CHENG ; Lai M.-S. | PLoS ONE | 26 | 24 | |
38 | 2013 | Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma | LI-CHUN LU ; YU-YUN SHAO ; Kuo R.N.C.; ZHONG-ZHE LIN ; Yeh Y.-C.; Shau W.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG ; Lai M.-S. | Cancer | 11 | 11 | |
39 | 2013 | Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer | YU-YUN SHAO ; Shau W.-Y.; ZHONG-ZHE LIN ; Chen H.-M.; Kuo R.; CHIH-HSIN YANG ; Lai M.-S. | European Journal of Cancer | 20 | 18 | |
40 | 2013 | The Aurora Kinases Inhibitor VE-465 is a Novel Treatment for Glioblastoma Multiforme | Lee P.-Y.; Chen C.-L.; ZHONG-ZHE LIN ; ANN-LII CHENG ; Chen E.I.-T.; Whang-Peng J.; Huang C.-Y.F. | Oncology | 11 | 9 | |
41 | 2013 | A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy | YU-YUN SHAO ; PO-CHIN LIANG ; YAO-MING WU ; Huang C.-C.; KAI-WEN HUANG ; CHIA-HSIEN CHENG ; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG ; ZHONG-ZHE LIN | Liver International | 15 | 15 | |
42 | 2012 | Prognosis of advanced hepatocellular carcinoma patients enrolled in clinical trials can be classified by current staging systems | YU-YUN SHAO ; LI-CHUN LU ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | British Journal of Cancer | 26 | 26 | |
43 | 2012 | Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: An East Asian population-based study | ZHONG-ZHE LIN ; Shau W.-Y.; YU-YUN SHAO ; Yang Y.-Y.; Kuo R.N.-C.; CHIH-HSIN YANG ; Laie M.-S. | Oncologist | 11 | 9 | |
44 | 2012 | Survival of patients with small cell lung carcinoma in Taiwan | Kuo Y.-H.; ZHONG-ZHE LIN ; Yang Y.-Y.; YU-YUN SHAO ; Shau W.-Y.; Kuo R.N.C.; CHIH-HSIN YANG ; Lai M.-S. | Oncology | 22 | 18 | |
45 | 2012 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Lee, Kuan-Der; Hsiao, Chi-Huang; YEN-SHEN LU ; Huang, Chien-Chung; YING-CHUN SHEN ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 26 | 25 | |
46 | 2012 | Diabetes mellitus is associated with increased mortality in patients receiving curative therapy for hepatocellular carcinoma | Shau W.-Y.; YU-YUN SHAO ; Yeh Y.-C.; ZHONG-ZHE LIN ; Kuo R.; CHIH-HUNG HSU ; CHIUN HSU ; ANN-LII CHENG ; Lai M.-S. | Oncologist | 32 | 32 | |
47 | 2012 | A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor | SHIH-HUNG YANG ; CHIA-CHI LIN ; ZHONG-ZHE LIN ; Tseng Y.-L.; RUEY-LONG HONG | Investigational New Drugs | 34 | 28 | |
48 | 2012 | The impact of diabetes mellitus on prognosis of early breast cancer in Asia | WEI-WU CHEN ; YU-YUN SHAO ; Shau W.-Y.; ZHONG-ZHE LIN ; YEN-SHEN LU ; Chen H.-M.; Kuo R.N.C.; ANN-LII CHENG ; Lai M.-S. | Oncologist | 36 | 34 | |
49 | 2012 | Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy | ZHONG-ZHE LIN ; CHIUN HSU ; Hu F.-C.; YU-YUN SHAO ; DWANG-YING CHANG ; CHIH-HSIN YANG ; RUEY-LONG HONG ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncologist | 8 | 10 | |
50 | 2011 | High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy | YU-YUN SHAO ; ZHONG-ZHE LIN ; Chen T.-J.; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 17 | 17 | |
51 | 2011 | Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; PEI-JER CHEN ; ZHONG-ZHE LIN ; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 12 | ||
52 | 2010 | Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; Huang C.; PO-CHIN LIANG ; ZHONG-ZHE LIN | Asia-Pacific Journal of Clinical Oncology | 29 | 29 | |
53 | 2010 | Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Ying-Chun Shen ; ZHONG-ZHE LIN ; PEI-JER CHEN ; YU-YUN SHAO ; Ding Y.-H.; CHIUN HSU ; ANN-LII CHENG | Journal of Hepatology | 110 | 103 | |
54 | 2010 | Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Yang T.-S.; CHIUN HSU ; Toh H.C.; Epstein R.J.; Hsiao L.-T.; PEI-JER CHEN ; ZHONG-ZHE LIN ; Chao T.-Y.; ANN-LII CHENG | British Journal of Cancer | 114 | 112 | |
55 | 2010 | Chemotherapy response in East Asian non-small cell lung cancer patients harboring wild-type or activating mutation of epidermal growth factor receptors | CHIA-CHI LIN ; Hsu H.-H.; Sun C.-T.; JIN-YUAN SHIH ; ZHONG-ZHE LIN ; CHONG-JEN YU ; Chen G.G.; Hsin M.K.Y.; Lam K.C.; Leung L.; CHIH-HSIN YANG ; Mok T. | Journal of Thoracic Oncology | 26 | 22 | |
56 | 2010 | Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer | 141 | 148 | |
57 | 2010 | Significance of Aurora B overexpression in hepatocellular carcinoma. Aurora B Overexpression in HCC | ZHONG-ZHE LIN ; YUNG-MING JENG ; Hu F.-C.; Pan H.-W.; Tsao H.-W.; Lai P.; PO-HUANG LEE ; ANN-LII CHENG ; Hsu H.-C. | BMC Cancer | 102 | 98 | |
58 | 2009 | Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment | YU-YUN SHAO ; ZHONG-ZHE LIN ; PO-CHIN LIANG ; YU-WEN TIEN ; ANN-LII CHENG | Anticancer Research | 1 | 1 | |
59 | 2009 | Sunitinib-induced myxedema coma | SHEY-YING CHEN ; Kao P.-C.; ZHONG-ZHE LIN ; WEN-CHU CHIANG ; CHENG-CHUNG FANG | American Journal of Emergency Medicine | 14 | 0 | |
60 | 2009 | EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment | Huang C.-L.; CHIH-HSIN YANG ; KUN-HUEI YEH ; Hu F.-C.; KUAN-YU CHEN ; JIN-YUAN SHIH ; ZHONG-ZHE LIN ; CHONG-JEN YU ; ANN-LII CHENG ; PAN-CHYR YANG | Lung Cancer | 43 | 36 | |
61 | 2009 | A randomized, double-blind, parallel, comparative study to evaluate the efficacy and safety of ramosetron plus dexamethasone injection for the prevention of acute chemotherapy-induced nausea and vomiting | Ho C.-L.; Su W.-C.; Hsieh R.-K.; ZHONG-ZHE LIN ; Chao T.-Y. | Japanese Journal of Clinical Oncology | 16 | 15 | |
62 | 2009 | The Aurora kinase inhibitor VE-465 has anticancer effects in pre-clinical studies of human hepatocellular carcinoma | ZHONG-ZHE LIN ; Hsu H.-C.; CHIH-HUNG HSU ; Yeh P.-Y.; Huang C.-Y.F.; Huang Y.-F.; Chen T.-J.; SUNG-HSIN KUO ; CHIUN HSU ; Hu F.-C.; YUNG-MING JENG ; Chung Y.; ANN-LII CHENG | Journal of Hepatology | 39 | 39 | |
63 | 2009 | Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival | Ying-Chun Shen ; Hu F.-C.; YUNG-MING JENG ; YU-TING CHANG ; ZHONG-ZHE LIN ; MING-CHU CHANG ; CHIUN HSU ; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 21 | 20 | |
64 | 2009 | Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma | SHIH-HUNG YANG ; ZHONG-ZHE LIN ; SUNG-HSIN KUO ; ANN-LII CHENG | American Journal of Hematology | 1 | 1 | |
65 | 2008 | High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy | Perng R.-P.; CHIH-HSIN YANG ; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; CHONG-JEN YU ; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN ; Kao W.-Y. | Lung Cancer | 28 | 26 | |
66 | 2008 | Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment | ZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 5 | 1 | |
67 | 2008 | Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy | CHIH-HSIN YANG ; CHONG-JEN YU ; JIN-YUAN SHIH ; YEUN-CHUNG CHANG ; Hu F.-C.; Tsai M.-C.; KUAN-YU CHEN ; ZHONG-ZHE LIN ; Huang C.-J.; CHIA-TUNG SHUN ; Huang C.-L.; Bean J.; ANN-LII CHENG ; Pao W.; PAN-CHYR YANG | Journal of Clinical Oncology | 240 | 224 | |
68 | 2007 | Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma | YEN-SHEN LU ; Kashida Y.; Kulp S.K.; Wang Y.-C.; Wang D.; Hung J.-H.; Tang M.; ZHONG-ZHE LIN ; Chen T.-J.; ANN-LII CHENG ; Chen C.-S. | Hepatology | 83 | 83 | |
69 | 2002 | Combination of 13-cis retinoic acid and interferon-α in the treatment of recurrent or refractory peripheral T-cell lymphoma | Huang C.-L.; ZHONG-ZHE LIN ; Su I.-J.; Chao T.-Y.; HWEI-FANG TIEN ; Chang M.-C.; Huang M.-C.; Kao W.-Y.; JIH-LUH TANG ; KUN-HUEI YEH ; Wang C.-H.; CHIH-HUNG HSU ; Liu M.-Y.; ANN-LII CHENG | Leukemia and Lymphoma | 9 | 5 |